NCT03557099View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

October 31, 2019

Study Completion Date

July 23, 2020

Conditions

Severe Aplastic Anemia

Interventions

DRUG

Hetrombopag Olamine

once daily

Trial Locations (1)

Unknown

Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03557099 - A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient | Biotech Hunter | Biotech Hunter